Medication approved for the treatment of HIV has caught the attention of researchers for potentially helping with the management of laryngopharyngeal reflux (LPR).

LPR occurs when stomach acid and digestive enzymes, including pepsin, travel up the oesophagus and into the throat. This reflux can lead to irritation and inflammation of the larynx and pharynx, causing symptoms such as coughing, hoarseness, throat clearing, post-nasal drip, globus sensation and dysphagia.

Unlike gastroesophageal reflux disease (GERD), which often presents with heartburn, LPR symptoms can be more subtle and easily overlooked.

The role of pepsin

Pepsin, a major digestive enzyme found in gastric juice, plays a significant role in LPR. Studies have shown that pepsin can be detected in the throat and airway tissue of individuals with LPR, suggesting its involvement in the development of, as well as the progression of, the condition.

N-Zyme Biomedical, a company dedicated to advancing reflux treatment, is exploring the therapeutic potential of pepsin inhibitors like Fosamprenavir as a targeted therapy for LPR.

Fosamprenavir is a protease inhibitor originally developed and approved for the treatment of HIV. However, recent studies have suggested that fosamprenavir has the ability to bind to and inactivate pepsin.

In preclinical studies, fosamprenavir demonstrated the potential to prevent laryngeal inflammation and damage caused by pepsin reflux.

Medication development

According to N-Zyme Biomedical, the development of new formulations of fosamprenavir, such as a prolonged-release oral formulation and a dry powder inhaler, may offer innovative delivery methods that enhance its effectiveness in treating LPR. These formulations aim to deliver fosamprenavir directly to the throat, where it can exert its inhibitory effects on pepsin activity.

N-Zyme Biomedical has engaged pharmaceutical company LGM Pharma to create a new prolonged release formulation of oral fosamprenavir.

It is also looking to move forward by submitting an application to the U.S. Food and Drug Administration (FDA) for a phase II clinical trial. This trial will assess the effectiveness of a new oral formulation of fosamprenavir sodium alginate.

Diagnosing reflux

Peptest, a non-invasive diagnostic test developed by RD Biomed Limited, serves as a vital tool in the diagnosis of LPR. By detecting elevated levels of pepsin in saliva samples, Peptest offers valuable insights into the presence and severity of LPR, helping healthcare providers tailor treatment approaches to individual patient needs.

As researchers continue to explore treatments like fosamprenavir, the diagnostic capabilities of Peptest will remain essential in guiding effective management strategies for individuals living with LPR.

Sign up

Subscribe To Our Email Newsletter

Be the first to know about EXCLUSIVE discount offers and the latest research into reflux.

You have Successfully Subscribed!